Micromedic Technologies (TASE: MCTC) announced successful results of a clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect technology.Read More
Dimerix (ASX:DXB) announced positive safety and efficacy data following a 27-patient Phase 2a proof-of-concept, dose escalation study in chronic kidney disease (CKD) for lead program, DMX-200.Read More
BioLight Life Sciences (TASE:BOLT) reported promising results from a feasibility clinical study designed to detect prostate cancer cells in urine specimens using its CellDetect technology.
The study successfully demonstrated the feasibility of detecting intact cells originating in the prostate from urine samples following prostate massage.Read More
The FDA has accepted an IND from Revive Therapeutics (OTCQB:RVVTF; TSX-V:RVV) for a Phase 2 clinical study of bucillamine for the treatment of cystinuria.
"This marks another significant milestone for Revive and we look forward to initiating this Phase 2 study shortly," Fabio Chianelli, president, said in a statement.Read More